header

Design, synthesis and biological evaluation of new phthalazinone derivatives of anticipated anticancer activity / (Record no. 170637)

MARC details
000 -LEADER
fixed length control field 04321namaa22004331i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - أخر تعامل مع التسجيلة
control field 20250223033426.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 250205s2024 |||a|||fr|m|| 000 0 eng d
040 ## - CATALOGING SOURCE
Original cataloguing agency EG-GICUC
Language of cataloging eng
Transcribing agency EG-GICUC
Modifying agency EG-GICUC
Description conventions rda
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
Language code of summary or abstract eng
-- ara
049 ## - Acquisition Source
Acquisition Source Deposit
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.19
092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC)
Classification number 615.19
Edition number 21
097 ## - Degree
Degree M.Sc
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
Local Call Number Cai01.08.05.M.Sc.2024.Di.D
100 0# - MAIN ENTRY--PERSONAL NAME
Authority record control number or standard number Dina Mohammed Ehab Mahmoud El-Deeb,
Preparation preparation.
245 10 - TITLE STATEMENT
Title Design, synthesis and biological evaluation of new phthalazinone derivatives of anticipated anticancer activity /
Statement of responsibility, etc. by Dina Mohammed Ehab Mahmoud El-Deeb ; Supervised by Prof. Dr. Asmaa Ahmed El-Zaher, Dr. Heba Abdel-Rasheed Abdelkhalek, Dr. Heba Mohamed Abbas El-Metwally
246 15 - VARYING FORM OF TITLE
Title proper/short title تصميم وتشييد وتقييم بيولوجي لمشتقات الفثالازينون الجديدة المتوقع فاعليتها كمضادات للسرطان /
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 2024.
300 ## - PHYSICAL DESCRIPTION
Extent 95 pages :
Other physical details illustrations ;
Dimensions 25 cm. +
Accompanying material CD.
336 ## - CONTENT TYPE
Content type term text
Source rda content
337 ## - MEDIA TYPE
Media type term Unmediated
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term volume
Source rdacarrier
502 ## - DISSERTATION NOTE
Dissertation note Thesis (M.Sc.)-Cairo University, 2024.
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Bibliography: pages 77-95.
520 ## - SUMMARY, ETC.
Summary, etc. Cancer is a disease where cells in a specific part of the body grow and reproduce uncontrollably, leading to metastasis. The epidermal growth factor receptor (EGFR), a member of the ErbB family, is a crucial function in epithelial cell physiology and is a primary target in cancer treatment. Gefitinib, a first-generation EGFR inhibitor, was approved by the FDA in 2003 for treating non-small cell lung cancer. Hydrazine-based heterocyclic compounds, including phthalazinone derivatives, have gained prominence due to their pharmacological characteristics and therapeutic uses. 22 phthalazinone-based compounds were designed to inhibit EGFR. These compounds were tested for their efficacy as EGFR inhibitors and their cytotoxicity against specific human cancer cell lines, including MCF-7, HepG2, and A549, as well as normal fibroblast cells (WI38). A molecular modeling analysis was conducted to determine the interaction between these compounds and the active region of EGFR-TK.
520 ## - SUMMARY, ETC.
Summary, etc. السرطان هو مرض يحدث عندما تنمو وتتكاثر الخلايا في جزء معين من الجسم بشكل غير متحكم فيه، مما يؤدي إلى التحور. (EGFR)، وهو عضو في عائلة ErbB، له وظيفة حاسمة في فسيولوجيا الخلية الظهارية وهو هدف أساسي في علاج السرطان. تمت الموافقة على جيفيتينيب ، وهو مثبط EGFR من الجيل الأول، من قبل إدارة الغذاء والدواء الأمريكية في عام 2003 لعلاج سرطان الرئة غير الصغير. اكتسبت المركبات الهيدرازينية القائمة على الحلقات الثنائية، بما في ذلك مشتقات الفثالازينون، شهرة بفضل خصائصها الدوائية واستخداماتها العلاجية. تم تصميم 22 مركبا قائما على الفثالازينون لتثبيط EGFR . تم اختبار هذه المركبات لفعاليتها كمثبطات لـ EGFR وسميتها ضد خطوط خلايا سرطانية بشرية محددة ،بما في ذلك MCF-7 وHepG2 و A549، بالإضافة إلى خلايا الليف الطبيعية .(WI38) تم إجراء تحليل نمذجة جزيئية لتحديد التفاعل بين هذه المركبات والمنطقة النشطة لـ .EGFR-TK
530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE
Issues CD Issued also as CD
546 ## - LANGUAGE NOTE
Text Language Text in English and abstract in Arabic & English.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmaceutical Chemistry
Source of heading or term qrmak
653 #0 - INDEX TERM--UNCONTROLLED
Uncontrolled term Cancer
-- Gefitinib
-- EGFR
-- Phthalazinone
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Asmaa Ahmed El-Zaher
Relator term thesis advisor.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Heba Abdel-Rasheed Abdelkhalek
Relator term thesis advisor.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Heba Mohamed Abbas El-Metwally
Relator term thesis advisor.
900 ## - Thesis Information
Grant date 01-01-2024
Supervisory body Asmaa Ahmed El-Zaher
-- Heba Abdel-Rasheed Abdelkhalek
-- Heba Mohamed Abbas El-Metwally
Universities Cairo University
Faculties Faculty of Pharmacy
Department Department of Pharmaceutical Chemistry
905 ## - Cataloger and Reviser Names
Cataloger Name Eman Ghareeb
Reviser Names Huda
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Thesis
Edition 21
Suppress in OPAC No
Holdings
Source of classification or shelving scheme Home library Current library Date acquired Inventory number Full call number Barcode Date last seen Effective from Koha item type
Dewey Decimal Classification المكتبة المركزبة الجديدة - جامعة القاهرة قاعة الرسائل الجامعية - الدور الاول 05.02.2025 90526 Cai01.08.05.M.Sc.2024.Di.D 01010110090526000 05.02.2025 05.02.2025 Thesis